



CSAM Health Group AS

Quarterly Report Q2-22 30 August 2022



CSAM's software facilitates life-changing milestones





Vital solutions for 500 healthcare and emergency response organisations across 25 countries



Developing diversified and growing business areas

















13%

Income ~90 MNOK vs ~80 MNOK in Q2-21





+14%

Recurring revenues: 70 MNOK vs 61 MNOK in Q2-21





~6%

Organic growth Q2-22 vs Q2-21



90%

90% gross margin vs 89% gross margin in Q2-21



4%

Reported EBITDA was 3.2 MNOK vs 10 MNOK in Q2-21








Reported sales outside the Nordics increased to 12% vs 7% in Q2-21






Growing the EBITDA margin through BIB





Current BIB integration project portfolio





Why isn't the EBITDA margin growing steadily in Q2 compared to previous quarters when we continuously apply our buy, integrate and build processes?

- Scale-up within the Blood Management (LIMS) business area to handle pipeline of customer deliveries
- Organisational change fully implemented in Q2-22 (more details on the next page)
- Completed management scale-up in Q2-22 to prepare for the next leg of our growth journey




Scalable organisation centred around business areas launched in Q2-22 to prepare for NOK 1bn revenue target















Seven Business Areas:

- Decision-making closer to the market and our customers
- Distributed organic growth and P&L responsibilities
- Decentralised responsibility for BIB-process enhances M&A scalability



Impact of moving from a centralised setup to Business Areas

Recent changes

Going forward

Reorganisation and top management

- Decentralised Business Areas implemented
- Top management team increased from 4 FTEs to 9 FTEs with full cost impact in Q2

Delivery capacity

- Hired 20 FTEs to be able to handle increased order backlog (driving licence sales and recurring revenue)
- Increased use of consultants in H1-22, but this will decrease as permanent employees are now in place.

One-offs


Consulting/recruitment costs ~NOK 5 million

- Organisation and top management now positioned to execute on the NOK 1 billion revenue target in 2025
- More capacity to execute on M&A strategy
- Scalability on selling, general & admin should be expected going forward
- Increased delivery capacity to boost organic revenue growth over time
- Lower consulting cost

 Impact from one-offs should diminish as we grow towards our NOK 1 billion revenue target in 2025




Prepared for the next leg






Where we came from and where we are heading






From Nordic to Pan-European - and beyond

Q2-2021 Q2-2022










CSAM's recurring software revenues are steadily increasing



Quarterly revenue development recurring revenue LFQ (NOKm)




13% revenue growth in Q2-22 and increasing share of ARR


Total revenue, Q/Q development

Recurring revenue, Q/Q development

NOKm



NOKm






Gross margin continue to be above 90%, but profitability temporarily hampered by reorganisation into business units

Cost base split

Comments

Cost base development Q/Q (NOKm)



- Gross margin continue to be above 90%
- Significant increase in number of FTEs as a consequence of recruitment activities necessary to handle delivery pipeline (driving licence sales and recurring revenue)



Margins are temporarily diluted, but will be restored in-line with our BIB framework

Capitalized R&D Q2 2021 vs. Q2 2022 Reported EBITDA Q2 2021 vs. Q2 2022 **Comments** MNOK MNOK 20 FTE's hired recently to 10.1 handle order backlog 13% Top management team and organisation now positioned to execute on the NOK 1 billion 9.3 3.2 revenue target in 2025 5.0 Capex back to normal level

Q2 2021

In % of total revenue

Q2 2022




Q2 2021

Q2 2022

NWC






Comments

- CSAM has a communicated NWC target of -10% or better
- The NWC calculation is performed by KWC, an independent firm specializing in evaluations
- When acquiring companies, it takes some time before CSAMs NWC policies are applied in the acquired companies, hence NWC development will vary




CSAM investors





Prepared for the next leg





Subscribe to our newsletter

csamhealth.com/newsletter

Subscribe to our news First Name **Last Name Email address News Types** Financial News General News I have read and agree to the terms & conditions



